Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Is Nuveen ESG International Developed Markets Equity ETF (NUDM) a Strong ETF Right Now?
01:59pm, Tuesday, 31'st May 2022 Zacks Investment Research
Smart Beta ETF report for NUDM
GSK to pay up to $3.3 billion for biopharma Affinivax
08:50am, Tuesday, 31'st May 2022 MarketWatch
GSK PLC said Tuesday that it has agreed to buy clinical-stage biopharmaceutical company Affinivax, Inc. for up to $3.3 billion.
Wide-Moat Stocks On Sale - The June 2022 Heat Map
07:20am, Tuesday, 31'st May 2022 Seeking Alpha
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison.
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
12:54pm, Sunday, 29'th May 2022 MarketWatch
This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
07:03pm, Tuesday, 24'th May 2022 Zacks Investment Research
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
01:25pm, Friday, 20'th May 2022 Zacks Investment Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Top Analyst Reports for Apple, Berkshire Hathaway, & S&P Global
09:08pm, Thursday, 19'th May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Berkshire Hathaway Inc. (BRK.B), and S&P Global Inc. (SPGI).
4 Large Drug Stocks to Watch as the Industry Recovers
01:32pm, Thursday, 19'th May 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are wor
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
07:05pm, Wednesday, 18'th May 2022 Zacks Investment Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
03:30pm, Tuesday, 17'th May 2022 Zacks Investment Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
How to find the best stocks in a bad market using this proven dividend yield strategy
02:18pm, Saturday, 14'th May 2022 MarketWatch
Focus only on blue-chip stocks with strong enough financials to keep paying dividends through thick and thin.
Was This Acquisition a Smart Move for GlaxoSmithKline?
02:00pm, Saturday, 14'th May 2022 The Motley Fool
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
07:00pm, Thursday, 12'th May 2022 Benzinga
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc
Why GSK May Have Bet Too Big on a Pandemic Pipeline
11:57am, Saturday, 07'th May 2022 The Motley Fool
Its late-stage pipeline is heavily weighted toward pandemic treatments.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
